EP
CNCE

Eversept Partners’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Eversept Partners’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,300
Closed -$27.8K – 69
2019
Q1 		$27.8K Buy
+2,300
New +$33.9K 0.01% 52

Other funds holding CNCE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Eversept Partners's CNCE Position: Q1 2021 in Review

Eversept Partners sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2021, closing a stake of 103,829 shares — an estimated $1.31M sold.

Eversept Partners first reported a position in CNCE in Q1 2019 and held it in 4 quarters. The position peaked at $2.32M in Q2 2020. 91 funds tracked by Wall St. Rank hold CNCE as of Q1 2021.

  • Eversept Partners reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
  • Eversept Partners sold 103,829 Concert Pharmaceuticals, Inc. shares in Q1 2021, an estimated $1.31M.
  • Eversept Partners first reported a position in Concert Pharmaceuticals, Inc. in Q1 2019 and held it in 4 quarters.
  • Eversept Partners's Concert Pharmaceuticals, Inc. position peaked at $2.32M in Q2 2020.
  • 91 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2021.

Based on Eversept Partners's 13F filing for Q1 2021, filed 13 May 2021.